Histological correlation of 17 prospective immunoscintigraphies of recurrences of colorectal carcinomas using indium-111-labeled anti-cea and(or) 19-9 monoclonal antibodies
Identifieur interne : 000488 ( Main/Exploration ); précédent : 000487; suivant : 000489Histological correlation of 17 prospective immunoscintigraphies of recurrences of colorectal carcinomas using indium-111-labeled anti-cea and(or) 19-9 monoclonal antibodies
Auteurs : RBID : ISTEX:259_1989_Article_BF00435470.pdfEnglish descriptors
Abstract
Seventeen patients (mean age 55 years) with suspected recurrence in previously operated and histologically confirmed colorectal adenocarcinomas were explored by immunoscintography (IS) associating planar and emission computed tomography (ECT) and using the 111In-labeled anti carcinoembryonic antigen (CEA) and(or) 19-9 monoclonal antibodies (MoAbs). The results of IS were compared blind with those of computed tomography (CT) and ultrasonography (US). The final diagnosis of recurrence and(or) metastasis was done in 16 cases by second-look surgery and in another patient by rectal biopsy. Overall per-patient sensitivity for the pelvis and extrahepatic abdomen was 69% for IS and 31% and 25% respectively for computed tomography and ultrasonography. No false positive of IS, as well as US and CT, for the pelvis and the extrahepatic abdomen was seen. Based on the number of anatomical sites tested, sensitivity of IS was 91% in the pelvis. In our series, scintigraphic computer subtraction did not allow adequate resolution of the problem of intense liver uptake of 111In-labeled MoAbs. It is concluded that IS using 111In-labeled anti CEA and(or) 19-9 MoAbs should be carried out prospectively in patients at high risk of recurrence of colorectal cancer.
DOI: 10.1007/BF00435470
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title>Histological correlation of 17 prospective immunoscintigraphies of recurrences of colorectal carcinomas using indium-111-labeled anti-cea and(or) 19-9 monoclonal antibodies</title><author><name>A. Chetanneau</name><affiliation wicri:level="3"><mods:affiliation>Department of Nuclear Medicine, Department of Radiology and Department of Medical Oncology, Centre René Gauducheau, Quai Moncousu, F-44035, Nantes Cedex, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Nuclear Medicine, Department of Radiology and Department of Medical Oncology, Centre René Gauducheau, Quai Moncousu, F-44035, Nantes Cedex</wicri:regionArea><placeName><region type="region" nuts="2">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name>P. A. Lehur</name><affiliation wicri:level="3"><mods:affiliation>Department of Gastrointestinal and General Surgery, Centre Hospitalo-Universitaire Laënnec, F-44800, Saint Herblain, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Gastrointestinal and General Surgery, Centre Hospitalo-Universitaire Laënnec, F-44800, Saint Herblain</wicri:regionArea><placeName><region type="region" nuts="2">Pays de la Loire</region><settlement type="city">Saint Herblain</settlement></placeName></affiliation></author><author><name>D. Ripoche</name><affiliation wicri:level="3"><mods:affiliation>Department of Nuclear Medicine, Department of Radiology and Department of Medical Oncology, Centre René Gauducheau, Quai Moncousu, F-44035, Nantes Cedex, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Nuclear Medicine, Department of Radiology and Department of Medical Oncology, Centre René Gauducheau, Quai Moncousu, F-44035, Nantes Cedex</wicri:regionArea><placeName><region type="region" nuts="2">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name>P. Peltier</name><affiliation wicri:level="3"><mods:affiliation>Department of Nuclear Medicine, Department of Radiology and Department of Medical Oncology, Centre René Gauducheau, Quai Moncousu, F-44035, Nantes Cedex, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Nuclear Medicine, Department of Radiology and Department of Medical Oncology, Centre René Gauducheau, Quai Moncousu, F-44035, Nantes Cedex</wicri:regionArea><placeName><region type="region" nuts="2">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name>J. C. Saccavini</name><affiliation wicri:level="3"><mods:affiliation>CIS Bioindustries, F-91190, Gif sur Yvette, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CIS Bioindustries, F-91190, Gif sur Yvette</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Gif sur Yvette</settlement></placeName></affiliation></author><author><name>J. P. Vuillez</name><affiliation wicri:level="3"><mods:affiliation>Department of Nuclear Medicine, Department of Radiology and Department of Medical Oncology, Centre René Gauducheau, Quai Moncousu, F-44035, Nantes Cedex, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Nuclear Medicine, Department of Radiology and Department of Medical Oncology, Centre René Gauducheau, Quai Moncousu, F-44035, Nantes Cedex</wicri:regionArea><placeName><region type="region" nuts="2">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name>N. Tournemaine</name><affiliation wicri:level="3"><mods:affiliation>Department of Nuclear Medicine, Department of Radiology and Department of Medical Oncology, Centre René Gauducheau, Quai Moncousu, F-44035, Nantes Cedex, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Nuclear Medicine, Department of Radiology and Department of Medical Oncology, Centre René Gauducheau, Quai Moncousu, F-44035, Nantes Cedex</wicri:regionArea><placeName><region type="region" nuts="2">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name>P. Thedrez</name><affiliation wicri:level="3"><mods:affiliation>Department of Nuclear Medicine, Department of Radiology and Department of Medical Oncology, Centre René Gauducheau, Quai Moncousu, F-44035, Nantes Cedex, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Nuclear Medicine, Department of Radiology and Department of Medical Oncology, Centre René Gauducheau, Quai Moncousu, F-44035, Nantes Cedex</wicri:regionArea><placeName><region type="region" nuts="2">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name>J. F. Chatal</name><affiliation wicri:level="3"><mods:affiliation>Department of Nuclear Medicine, Department of Radiology and Department of Medical Oncology, Centre René Gauducheau, Quai Moncousu, F-44035, Nantes Cedex, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Nuclear Medicine, Department of Radiology and Department of Medical Oncology, Centre René Gauducheau, Quai Moncousu, F-44035, Nantes Cedex</wicri:regionArea><placeName><region type="region" nuts="2">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="RBID">ISTEX:259_1989_Article_BF00435470.pdf</idno><date when="1989">1989</date><idno type="doi">10.1007/BF00435470</idno><idno type="wicri:Area/Main/Corpus">000E04</idno><idno type="wicri:Area/Main/Curation">000E04</idno><idno type="wicri:Area/Main/Exploration">000488</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Colorectal carcinoma</term><term>Immunoscintigraphy</term><term>Monoclonal antibodies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="eng">Seventeen patients (mean age 55 years) with suspected recurrence in previously operated and histologically confirmed colorectal adenocarcinomas were explored by immunoscintography (IS) associating planar and emission computed tomography (ECT) and using the 111In-labeled anti carcinoembryonic antigen (CEA) and(or) 19-9 monoclonal antibodies (MoAbs). The results of IS were compared blind with those of computed tomography (CT) and ultrasonography (US). The final diagnosis of recurrence and(or) metastasis was done in 16 cases by second-look surgery and in another patient by rectal biopsy. Overall per-patient sensitivity for the pelvis and extrahepatic abdomen was 69% for IS and 31% and 25% respectively for computed tomography and ultrasonography. No false positive of IS, as well as US and CT, for the pelvis and the extrahepatic abdomen was seen. Based on the number of anatomical sites tested, sensitivity of IS was 91% in the pelvis. In our series, scintigraphic computer subtraction did not allow adequate resolution of the problem of intense liver uptake of 111In-labeled MoAbs. It is concluded that IS using 111In-labeled anti CEA and(or) 19-9 MoAbs should be carried out prospectively in patients at high risk of recurrence of colorectal cancer.</div></front></TEI><mods xsi:schemaLocation="http://www.loc.gov/mods/v3 file:///applis/istex/home/loadistex/home/etc/xsd/mods.xsd" version="3.4" istexId="f2468639d0261d15e59c2573606076a255f55d78"><titleInfo lang="eng"><title>Histological correlation of 17 prospective immunoscintigraphies of recurrences of colorectal carcinomas using indium-111-labeled anti-cea and(or) 19-9 monoclonal antibodies</title></titleInfo><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Chetanneau</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Department of Radiology and Department of Medical Oncology, Centre René Gauducheau, Quai Moncousu, F-44035, Nantes Cedex, France</affiliation></name><name type="personal"><namePart type="given">P. A.</namePart><namePart type="family">Lehur</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Gastrointestinal and General Surgery, Centre Hospitalo-Universitaire Laënnec, F-44800, Saint Herblain, France</affiliation></name><name type="personal"><namePart type="given">D.</namePart><namePart type="family">Ripoche</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Department of Radiology and Department of Medical Oncology, Centre René Gauducheau, Quai Moncousu, F-44035, Nantes Cedex, France</affiliation></name><name type="personal"><namePart type="given">P.</namePart><namePart type="family">Peltier</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Department of Radiology and Department of Medical Oncology, Centre René Gauducheau, Quai Moncousu, F-44035, Nantes Cedex, France</affiliation></name><name type="personal"><namePart type="given">J. C.</namePart><namePart type="family">Saccavini</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>CIS Bioindustries, F-91190, Gif sur Yvette, France</affiliation></name><name type="personal"><namePart type="given">J. P.</namePart><namePart type="family">Vuillez</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Department of Radiology and Department of Medical Oncology, Centre René Gauducheau, Quai Moncousu, F-44035, Nantes Cedex, France</affiliation></name><name type="personal"><namePart type="given">N.</namePart><namePart type="family">Tournemaine</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Department of Radiology and Department of Medical Oncology, Centre René Gauducheau, Quai Moncousu, F-44035, Nantes Cedex, France</affiliation></name><name type="personal"><namePart type="given">P.</namePart><namePart type="family">Thedrez</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Department of Radiology and Department of Medical Oncology, Centre René Gauducheau, Quai Moncousu, F-44035, Nantes Cedex, France</affiliation></name><name type="personal"><namePart type="given">J. F.</namePart><namePart type="family">Chatal</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Department of Radiology and Department of Medical Oncology, Centre René Gauducheau, Quai Moncousu, F-44035, Nantes Cedex, France</affiliation></name><typeOfResource>text</typeOfResource><genre>Original Paper</genre><originInfo><publisher>Springer-Verlag, Berlin/Heidelberg</publisher><dateCreated encoding="w3cdtf">1988-09-04</dateCreated><dateCaptured encoding="w3cdtf">1988-12-31</dateCaptured><dateValid encoding="w3cdtf">2004-09-25</dateValid><copyrightDate encoding="w3cdtf">1989</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="eng">Seventeen patients (mean age 55 years) with suspected recurrence in previously operated and histologically confirmed colorectal adenocarcinomas were explored by immunoscintography (IS) associating planar and emission computed tomography (ECT) and using the 111In-labeled anti carcinoembryonic antigen (CEA) and(or) 19-9 monoclonal antibodies (MoAbs). The results of IS were compared blind with those of computed tomography (CT) and ultrasonography (US). The final diagnosis of recurrence and(or) metastasis was done in 16 cases by second-look surgery and in another patient by rectal biopsy. Overall per-patient sensitivity for the pelvis and extrahepatic abdomen was 69% for IS and 31% and 25% respectively for computed tomography and ultrasonography. No false positive of IS, as well as US and CT, for the pelvis and the extrahepatic abdomen was seen. Based on the number of anatomical sites tested, sensitivity of IS was 91% in the pelvis. In our series, scintigraphic computer subtraction did not allow adequate resolution of the problem of intense liver uptake of 111In-labeled MoAbs. It is concluded that IS using 111In-labeled anti CEA and(or) 19-9 MoAbs should be carried out prospectively in patients at high risk of recurrence of colorectal cancer.</abstract><subject lang="eng"><genre>Key words</genre><topic>Colorectal carcinoma</topic><topic>Immunoscintigraphy</topic><topic>Monoclonal antibodies</topic></subject><relatedItem type="series"><titleInfo type="abbreviated"><title>Eur J Nucl Med</title></titleInfo><titleInfo><title>European Journal of Nuclear Medicine</title><partNumber>Year: 1989</partNumber><partNumber>Volume: 15</partNumber><partNumber>Number: 6</partNumber></titleInfo><genre>Archive Journal</genre><originInfo><dateIssued encoding="w3cdtf">1989-06-01</dateIssued><copyrightDate encoding="w3cdtf">1989</copyrightDate></originInfo><subject usage="primary"><topic>Medicine & Public Health</topic><topic>Imaging / Radiology</topic><topic>Nuclear Medicine</topic></subject><identifier type="issn">0340-6997</identifier><identifier type="issn">Electronic: 1619-7089</identifier><identifier type="matrixNumber">259</identifier><identifier type="local">IssueArticleCount: 14</identifier><recordInfo><recordOrigin>Springer-Verlag, 1989</recordOrigin></recordInfo></relatedItem><identifier type="doi">10.1007/BF00435470</identifier><identifier type="matrixNumber">Art6</identifier><identifier type="local">BF00435470</identifier><accessCondition type="use and reproduction">MetadataGrant: OpenAccess</accessCondition><accessCondition type="use and reproduction">AbstractGrant: OpenAccess</accessCondition><accessCondition type="restriction on access">BodyPDFGrant: Restricted</accessCondition><accessCondition type="restriction on access">BodyHTMLGrant: Restricted</accessCondition><accessCondition type="restriction on access">BibliographyGrant: Restricted</accessCondition><accessCondition type="restriction on access">ESMGrant: Restricted</accessCondition><part><extent unit="pages"><start>302</start><end>306</end></extent></part><recordInfo><recordOrigin>Springer-Verlag, 1989</recordOrigin><recordIdentifier>259_1989_Article_BF00435470.pdf</recordIdentifier></recordInfo></mods></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000488 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000488 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:259_1989_Article_BF00435470.pdf
|texte= Histological correlation of 17 prospective immunoscintigraphies of recurrences of colorectal carcinomas using indium-111-labeled anti-cea and(or) 19-9 monoclonal antibodies
}}
| This area was generated with Dilib version V0.5.81. |  |